Navigation Links
Astute Medical, Inc. Advancing Next Generation Acute Kidney Injury Biomarkers
Date:2/6/2013

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Citing results of a clinical study published today in Critical Care, Astute Medical Chief Executive Officer Chris Hibberd said he is confident about the prospects for newly validated biomarkers of kidney damage used in the Company's NephroCheck® Test. The international, multi-center study validated the ability to predict acute kidney injury (AKI) using measurements of the two biomarkers, Insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2) and demonstrated their superiority in risk assessment of AKI when compared with existing biomarkers.

The NephroCheck® Test is intended to aid in the risk assessment of AKI, a condition as prevalent and more deadly than heart attack. The test was launched in Europe in October 2012. It is not available for sale in the United States.

Much like a silent heart attack, AKI can strike without obvious symptoms. The condition is associated with high mortality rates, in part, because it often is not detected until it has reached the later stages when few management options exist.

"If unchecked, AKI can lead to loss of kidney function, often resulting in lower quality of life or even death," said Dr. John Kellum , a critical care physician at UPMC and principal investigator for the study. "Our data show that two urinary biomarkers of kidney damage can tell a doctor if a patient is at risk for AKI. In addition, these biomarkers provide additional information over clinical variables and add mechanistic insight into AKI, making them the most promising markers of AKI reported to date."

Researchers reported on a two-part study that initially evaluated 340 biomarkers and found the combination of TIMP-2 and IGFBP7 to have the highest correlation with risk of AKI. Results from the second part of the study validated the utility of TIMP-2 and IGFBP7 and the improved ability of the two-biomarker combination to predict AKI when compared to existing biomarkers.

"Based upon these results, we believe the NephroCheck® Test will be able to help physicians address one of the most costly, deadly and confounding conditions affecting intensive care hospital patients," said Hibberd. "With increasing constraints on healthcare spending, innovative tools such as the NephroCheck® Test will be essential to ensuring that the right resources get to the right patients at the right time."

AKI has been associated with higher cost of care, especially in the intensive care unit (ICU). A 2008 study of post-cardiac surgery patients published in Nephrology Dialysis Transplantation reported that critically ill patients with no AKI had an ICU cost of $13,836 and 1.4 days of length of stay. In comparison, patients with severe AKI had an ICU cost of up to $49,328 and up to 5.4 days of length of stay.

AKI affects up to seven percent of hospitalized patients. The incidence is much higher among critically ill patients, with up to half developing some degree of AKI during their illness.

About Astute Medical, Inc.
Named by the Wall Street Journal as one of the Top 10 Healthcare Start-Ups of 2012, Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.  For additional information, please visit www.astutemedical.com

Astute Medical®, the Astute Medical logo, Astute140® and NephroCheck® are registered trademarks of Astute Medical, Inc. in the United States. The NephroCheck logo is a trademark of Astute Medical, Inc. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/about/intellectual-property.


'/>"/>
SOURCE Astute Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
2. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
3. MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Cover in the Medical, Dental & Related Services/Trade Category
4. MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Overall Category in Medical, Dental & Related Services/Trade
5. KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.6 Million
6. Saladax Biomedical, Inc. Announces the Formation of a CLIA Laboratory As Part of the Companys Commercialization Strategy
7. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
8. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
9. Gated STED -- developing the next generation of super-resolution microscopes
10. Functionalized graphene oxide plays part in next-generation oil-well drilling fluids
11. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
Breaking Biology Technology:
(Date:8/23/2017)... ARMONK, N.Y. , Aug. 23, 2017  The general public,s help ... the human microbiome—the bacteria that live in and on the human body ... ... bacteria in the human microbiome, starting with the gut. The project's goal ... in disease. Photo credit: IBM ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
Breaking Biology News(10 mins):